CD13 Antibody (BR2): sc-53970
- CD13 Antibody (BR2) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against foreskin fibroblasts of human origin
- recommended for detection of CD13 of human origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD13 Antibody (BR2) for WB applications. These reagents are now offered in bundles with CD13 Antibody (BR2) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD13 Antibody (BR2) is a mouse monoclonal IgG1 antibody that detects CD13 in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD13, also known as aminopeptidase N, is a type II transmembrane glycoprotein predominantly expressed on myeloid cells, including monocytes, basophils, eosinophils, neutrophils, and various myeloid leukemias, as well as on certain epithelial cells, fibroblasts, and osteoclasts. CD13 functions as a zinc-binding metalloprotease, playing a crucial role in the digestion of peptides and the inactivation of regulatory peptides like enkephalins, which are important for pain modulation and stress response. CD13′s significance extends to cancer biology, where CD13 enhances the invasive capacity and metastatic behavior of cancer cells, making CD13 a potential target for therapeutic intervention. Notably, basic fibroblast growth factor (bFGF) can upregulate CD13 expression in human melanoma cells, which activates both the myeloid and epithelial CD13 promoters, highlighting CD13′s role in tumor progression and the potential for targeted therapies that inhibit CD13 activity to induce apoptosis in CD13-positive cancer cells. Anti-CD13 antibody (BR2) is an essential tool for researchers investigating the multifaceted roles of CD13 in both normal physiology and disease states.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD13 Antibody (BR2) References:
- DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. | Reinhold, D., et al. 2008. Front Biosci. 13: 2356-63. PMID: 17981717
- CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse. | Winnicka, B., et al. 2010. J Leukoc Biol. 88: 347-59. PMID: 20430777
- Aminopeptidase N (CD13) is involved in phagocytic processes in human dendritic cells and macrophages. | Villaseñor-Cardoso, MI., et al. 2013. Biomed Res Int. 2013: 562984. PMID: 24063007
- Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. | Favaloro, EJ., et al. 1988. Br J Haematol. 69: 163-71. PMID: 2455535
- Prognostic significance of aminopeptidase-N (CD13) in hepatoblastoma. | Saida, S., et al. 2015. Pediatr Int. 57: 558-66. PMID: 25682862
- CD13 mediates phagocytosis in human monocytic cells. | Licona-Limón, I., et al. 2015. J Leukoc Biol. 98: 85-98. PMID: 25934926
- CD13/aminopeptidase N is a negative regulator of mast cell activation. | Zotz, JS., et al. 2016. FASEB J. 30: 2225-35. PMID: 26936360
- Localization, Shedding, Regulation and Function of Aminopeptidase N/CD13 on Fibroblast like Synoviocytes. | Morgan, RL., et al. 2016. PLoS One. 11: e0162008. PMID: 27658265
- Computational study of novel natural inhibitors targeting aminopeptidase N(CD13). | Ge, J., et al. 2020. Aging (Albany NY). 12: 8523-8535. PMID: 32388498
- CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro. | Zhang, W., et al. 2024. BMC Cancer. 24: 369. PMID: 38519889
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD13 Antibody (BR2) | sc-53970 | 200 µg/ml | $322.00 | |||
CD13 Antibody (BR2): m-IgG Fc BP-HRP Bundle | sc-537023 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD13 Antibody (BR2): m-IgGκ BP-HRP Bundle | sc-534205 | 200 µg Ab; 40 µg BP | $361.00 | |||
CD13 Antibody (BR2): m-IgG1 BP-HRP Bundle | sc-544963 | 200 µg Ab; 20 µg BP | $361.00 | |||
CD13 Antibody (BR2) FITC | sc-53970 FITC | 200 µg/ml | $336.00 | |||
CD13 Antibody (BR2) PE | sc-53970 PE | 200 µg/ml | $349.00 |